. Selected clinical trials and preclinical data for ex vivo DC vaccination in Leukemia. 5-year OS for AML is approximately 24%, 5-year OS for CML is approximately 68%, 5 year OS for ALL is approximately 71%, 5 year OS for CLL is approximately 83% (Society, 2018).
15 × 10 6 DCs intra-dermally weekly for 4 weeks then monthly up to 6 months in post-remission patients.
Autologous T cell responses in humanized NSG mice (enhanced compared Vaccine-induced immune responses in 90% patients. 30% PR, 60% SD, 10% PD Good outcome.
